Skip to main content

Supporting HIV Education for Health Care Professionals

Search website

Training
Consultation
Directory
Library
Calendar
Community
App

You are here

Home » Library » Long-Acting Injectable Cabotegravir: the Future of HIV PrEP

Long-Acting Injectable Cabotegravir: the Future of HIV PrEP

Publish date: June 2, 2020

AETC source: Mountain West AETC

Brian Wood, MD (Author)

This slide set includes an overview of cabotegravir, and provides updates from the phase III PrEP trial and next steps for long-acting PrEP.

Documents

Long-Acting Cabotegravir: The Future of HIV PrEP
Long-Acting Injectable Cabotegravir: The future of HIV PrEP?

Browse more

Language: English

Topic(s): Antiretroviral Therapy, Pre-exposure Prophylaxis

Resource type: Training Materials

Add comment

Log in to post comments

We'd like your feedback

Was this page helpful? *

Yes

No

I found this page helpful because the content on the page:

Check all that apply

Had the information I needed

Was trustworthy

Was up-to-date

Was written clearly

I did not find this page helpful because the content on the page:

Check all that apply

Had too little information

Had too much information

Was confusing

Was out-of-date

Professional discipline

Primary professional discipline

Other reason or comment

Include your email address if you would like a response

Other reason or comment

Include your email address if you would like a response

Leave this field blank

About
Contact
Subscribe
Policies
Log In

Keep in Touch

Facebook
Twitter
YouTube
Linked In
Pinterest

This project is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award (grant number U1OHA28686) totaling $1,700,000 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government.